We are pleased to announce that our company has entered into an exclusive distribution and licensing agreement with Keio University regarding the myocardial cells originating from disease type iPS cells (derived from patients with hypertrophic cardiomyopathy).
Company: REPROCELL, Inc.
Representative: Chikafumi Yokoyama, PhD
Since we are able to reproduce at the cellular level the cells of patients with heart disease using the iPS cells, with the help of the advanced technology of Keio University, which boasts a proven track record in the myocardial cell research, by this agreement our company plans the commercialization of the iPS cell business and expands our business worldwide. The patient’s cells are taken based on informed consent, we prepare iPS cells from the cardiac muscle cells of the patient, and sell these cells, which reflect the genetic disorder of the patients, exclusively to research institutions that carry out animal experiments and such tests that will help the development of new drugs and clarify the pathological conditions of hypertrophic cardiomyopathy.
While so far it has been considered impossible to reproduce the patient’s own unique pathological condition, with this agreement this breakthrough product which brings great possibilities to the drug design research for myocardial disease, will be added to our company’s lineup and also contribute to the clarification of the anticipated regenerative medicine disease mechanism and to the realization of personalized medicine.
Going forward, we will actively involve the external research institutions in our business development by means of cooperation, as well as strengthen the product lineup to set the trend of a new era, and will continue to pioneer the future of medical care including regenerative medicine.